<DOC>
	<DOCNO>NCT02744248</DOCNO>
	<brief_summary>Study Objectives Primary : To determine MTD dose limit toxicity ( DLTs ) IOP magnetic resonance imaging ( MRI ) contrast agent healthy subject . Secondary : 1 . To characterize pharmacokinetic profile IOP MRI contrast agent healthy subject . 2 . To evaluate safety/tolerability profile IOP MRI contrast agent healthy subject . 3 . To explore efficacy profile IOP MRI contrast agent liver organ healthy subject .</brief_summary>
	<brief_title>Phase I , MTD , Pharmacokinetic , Safety/Tolerability , Efficacy IOP Injection MRI Healthy Subjects</brief_title>
	<detailed_description>Iron Oxide Nano Particle m-PEG-silane ( IOP ) Injection belong Superparamagnetic iron oxide ( SPIO ) shorten T2 relaxation time effectively reduce signal intensity normal tissue . The mechanism action increase particle phagocytosed cell RES . Tissues decrease RES function ( e.g. , metastasis , primary liver cancer , cysts various benign tumor , adenoma , hyperplasia ) retain native signal intensity . In study , investigator characterize PK profile , iron metabolism preliminary efficacy IOP Injection .</detailed_description>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Lymphatic Metastasis</mesh_term>
	<criteria>1 . Male , age ≥ 20 ~40 year old BMI 18 27 . 2 . Subject must good general health condition ( i.e. , full physical examination , medical history , vital sign , ECG , clinical laboratory test perform screen ) determine investigator . Normal ECG define normal cardiac conduction parameter include rest heart rate 50 100 bpm , Fridericiacorrected QT interval ( QTcF ) ≤ 450 millisecond , QRS interval &lt; 120 millisecond . 3 . Subject show normal biochemistry test result ( within normal range consider clinically normal clinical investigator ) screen include item list : Blood urea nitrogen ( BUN ) , creatinine , uric acid . Albumin total protein . Alkaline phosphatase , ALT , AST , total bilirubin . Serum iron , total ironbinding capacity , serum ferritin , percent transferrin saturation ( TSAT ) , transferrin . Human immunodeficiency virus ( HIV ) , Hepatitis B surface antigen ( HBsAg ) , Antibody HBsAg ( antiHBs ) , antibody HCV ( antiHCV ) . 4 . Subject show normal complete blood count ( CBC ) test result ( within normal range consider clinically normal clinical investigator ) screen include item list : Red blood cell ( RBC ) count reticulocyte count . White blood cell ( WBC ) count differential . Hemoglobin hematocrit . Platelet count . 5 . Subject show normal urinalysis test result ( within normal range consider clinically normal clinical investigator ) screen include item list : pH , color , appearance , gravity Erythrocyte , leukocyte , glucose , protein , ketone , nitrite Drug alcohol abuse screen test include morphine , 3,4 methylenedioxymethamphetamine ( MDMA ) , 3,4methylenedioxyamphetamine ( MDA ) , ketamine , codeine alcohol . 6 . Subject show normal bleeding time test result ( within normal range consider clinically normal clinical investigator ) screen include prothrombin ( PT ) activate partial thromboplastin time ( APTT ) . 7 . Male subject must take reliable contraceptive method ( ) study period 14 day . 8 . No screen drug alcohol abuse within one year prior study enrollment . 9 . Subjects willing comply protocol sign inform consent form . 1 . Subjects serious allergic history know allergy similar ingredient study contrast agent ( i.e. , Gdbased SPIO particle contrast agent ) . 2 . Subjects diagnose Hepatitis B C , venereal disease laboratory screen determine positive result human immunodeficiency virus test . 3 . Imaging and/or functional abnormality liver and/or spleen . That , Subjects diagnose abnormal liver function appearances medical history , clinical laboratory test , image test include mild fatty liver , iron deposition acute/chronic liver change . Subjects sign splenomegaly , enlargement spleen , clinical laboratory test show sign spleen functional abnormality . 4 . Subjects perform examination contrast agent apply within 28 day study . 5 . Subjects alcohol caffeine consumption within 48 hour prior administration study contrast agent . 6 . Subjects unable undergo MRI scan . 7 . Subjects electronically , magnetically mechanically activate implanted device , include limited automatic cardioverter defibrillator , cardiac pacemaker , insulin pump , metallic splinter eye , ferromagnetic haemostatic clip central nervous system vascular vessel . 8 . Subjects participate investigational trial within 28 day prior study enrollment . 9 . Subjects active systemic infection , active clinically significant cardiac disease , active gastrointestinal ulcer , medical condition may significantly affect action , adequate absorption elimination investigational contrast agent . 10 . Subjects take food 6 hour prior administration . 11 . Subject condition judge investigator unsuitable study .</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Magnetic Resonance Imaging ( MRI )</keyword>
</DOC>